

Depression: Challenges and Treatments

This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically and within topics and years by first author. Articles from the bibliography that are reprinted in this issue are in bold type.

- Lam RW, Levitt AJ, Levitan RD, Michalak EE, Morehouse RL, Ramasubbu R, Yatham LN, Tam EM. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized clinical trial. *JAMA Psychiatry* 2016; 73(1):56–63.
- Rapaport MH, Nierenberg AA, Schettler PJ, et al: Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. *Mol Psychiatry* 2016; 21:71–79
- Bérard A, Iessa N, Chaabane S, et al: The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis. *Br J Clin Pharmacol* (Epub ahead of print, Nov 27, 2015)
- CONVERGE Consortium: Sparse whole-genome sequencing identifies two loci for major depressive disorder. *Nature* 2015; 523:588–591
- Cuijpers P, De Wit L, Weitz E, et al: The combination of psychotherapy and pharmacotherapy in the treatment of adult depression: a comprehensive meta-analysis. *Journal of Evidence-Based Psychotherapies* 2015; 15:147–168
- Dash S, Clarke G, Berk M, Jacka FN. The gut microbiome and diet in psychiatry: focus on depression. *Curr Opin Psychiatry*. 2015 Jan;28(1):1–6.
- DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment-resistant depression: current evidence and future directions. *Ann NY Acad Sci*. 2015; 1345:47–58.
- Driessen E, Hegelmaier LM, Abbass AA, et al: The efficacy of short-term psychodynamic psychotherapy for depression: a meta-analysis update. *Clin Psychol Rev* 2015; 42:1–15
- Gartlehner G, Gaynes BN, Amick HR, et al: Nonpharmacological Versus Pharmacological Treatments for Adult Patients With Major Depressive Disorder. Comparative Effectiveness Review no 161. AHRQ no 15(16)-EHC031-EF. Rockville, MD, Agency for Healthcare Research and Quality, 2015
- [The Executive Summary of this report is reprinted in this issue.]**
- Goldberg JF, Freeman MP, Balon R, et al: The American Society of Clinical Psychopharmacology Survey of Psychopharmacologists' Practice Patterns for the Treatment of Mood Disorders. *Depress Anxiety* 2015; 32:605–613
- Greer TL, Grannemann BD, Chansard M, et al: Dose-dependent changes in cognitive function with exercise augmentation for major depression: results from the TREAD study. *Eur Neuropsychopharmacol* 2015; 25:248–256
- Kuyken W, Hayes R, Barrett B, et al: Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial. *Lancet* 2015; 386:63–73
- Lavretsky H, Reinlieb M, St Cyr N, Siddarth P, Ercoli LM, Senturk D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. *Am J Psychiatry* 2015; 172(6):561–9
- Leuchter AF, Cook IA, Feifel D, et al: Efficacy and safety of low-field synchronized transcranial magnetic stimulation (sTMS) for treatment of major depression. *Brain Stimulat* 2015; 8:787–794
- McMahon FJ: Clinically useful genetic markers of antidepressant response: How do we get there from here? *Am J Psychiatry* 2015; 172:697–699
- Petrak F, Baumeister H, Skinner TC, et al: Depression and diabetes: treatment and health-care delivery. *Lancet Diabetes Endocrinol* 2015; 3:472–485
- Petrak F, Herpertz S, Albus C, et al: Cognitive behavioral therapy versus sertraline in patients with depression and poorly controlled diabetes: the Diabetes and Depression (DAD) Study: a randomized controlled multicenter trial. *Diabetes Care* 2015; 38:767–775
- Reefhuis J, Devine O, Friedman JM, et al: Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. *BMJ* 2015; 351:h3190
- Robinson RG, Jorge RE: Post-stroke depression: a review. *Am J Psychiatry* (Epub ahead of print, Dec 18, 2015)
- Warren MB, Pringle A, Harmer CJ: A neurocognitive model for understanding treatment action in depression. *Philos Trans R Soc Lond B Biol Sci* 2015; 370:20140213
- Baumeister H, Hutter N, Bengel J: Psychological and pharmacological interventions for depression in patients with diabetes mellitus: an abridged Cochrane review. *Diabet Med* 2014; 31:773–786

- Brunner E, Tohen M, Osuntokun O, et al: Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. *Neuropsychopharmacol* 2014; 39: 2549–2559
- Hollon SD, DeRubeis RJ, Fawcett J, et al: Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. *JAMA Psychiatry* 2014; 71:1157–1164
- Lal S, Adair CE. E-mental health: a rapid review of the literature. *Psychiatr Serv*. 2014; 65(1):24–32.
- Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. *Psychol Med*. 2014; 44(4):797–810.
- Saddichha S, Al-Desouki M, Lamia A, et al: Online interventions for depression and anxiety—a systematic review. *Health Psychol Behav Med* 2014; 2:841–881
- Sarris J, Papakostas GI, Vitolo O, et al: S-adenosyl methionine (SAME) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. *J Affect Disord* 2014; 164:76–81 [See also letter to the editor Muskin]
- Scarr E, Millan MJ, Bahn S, Bertolino A, Turck CW, Kapur S, Möller HJ, Dean B. Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank. *Int J Neuropsychopharmacol*. 2015; 18(10):pyv042.
- Walker R, Morris DW, Greer TL, et al: Research staff training in a multisite randomized clinical trial: methods and recommendations from the Stimulant Reduction Intervention using Dosed Exercise (STRIDE) trial. *Addict Res Theory* 2014; 22:407–415
- Weissman MM, Wickramaratne P, Pilowsky DJ, Poh E, Hernandez M, Batten LA, Flament MF, Stewart JW, Blier P. The effects on children of depressed mothers' remission and relapse over 9 months. *Psychol Med*. 2014; 44(13):2811–24.
- Yoshimatsu K, Palmer B. Depression in patients with borderline personality disorder. *Harv Rev Psychiatry*. 2014; 22(5): 266–73.
- Barth J, Munder T, Gerger H, et al: Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. *PLoS Med* 2013; 10: e1001454**
- Cuijpers P, Huibers M, Ebert DD, et al: How much psychotherapy is needed to treat depression? A metaregression analysis. *J Affect Disord* 2013; 149:1–13
- Jarrett RB, Minhajuddin A, Gershenfeld H, et al: Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo. *JAMA Psychiatry* 2013; 70:1152–1160
- Nyer M, Doorley J, Durham K, et al: What is the role of alternative treatments in late-life depression? *Psychiatr Clin North Am* 2013; 36:577–596
- Sansone RA, Sansone LA: Sunshine, serotonin, and skin: a partial explanation for seasonal patterns in psychopathology? *Innov Clin Neurosci* 2013; 10:20–24
- Sarris J, Nierenberg AA, Schweitzer I, et al: Conditional probability of response or nonresponse of placebo compared with antidepressants or St John's wort in major depressive disorder. *J Clin Psychopharmacol* 2013; 33:827–830
- Spielmans GI, Berman MI, Linardatos E, et al: Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. *PLoS Med* 2013; 10(3):e1001403**
- Wiles N, Thomas L, Abel A, et al: Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBaT randomised controlled trial. *Lancet* 2013; 381:375–384
- Zisook S, Pies R, Iglewicz A: Grief, depression, and the DSM-5. *J Psychiatr Pract* 2013; 19:386–396
- Kennedy SH, Downar J, Evans KR, et al: The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. *Curr Pharm Des* 2012; 18:5976–5989
- Kupfer DJ, Frank E, Phillips ML: Major depressive disorder: new clinical, neurobiological, and treatment perspectives. *Lancet* 2012; 379:1045–1055**
- Mantovani A, Pavlicova M, Avery D, et al: Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (TMS) in treatment-resistant depression. *Depress Anxiety* 2012; 29:883–890**
- Zisook S, Corruble E, Duan N, et al: The bereavement exclusion and DSM-5. *Depress Anxiety* 2012; 29:425–443
- Freeman MP, Fava M, Lake J, et al: Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. *J Clin Psychiatry* 2010; 71:669–681
- Segal ZV, Bieling P, Young T, et al: Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. *Arch Gen Psychiatry* 2010; 67:1256–1264
- Kocsis JH, Gelenberg AJ, Rothbaum BO, et al: Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. *Arch Gen Psychiatry* 2009; 66:1178–1188